CDK9 and breast carcinoma: Most recently, another receptor tyrosine kinase, ALK was shown to promote HR activity and PARPi/platinum resistance through phosphorylating CDK9 at Y19 residue (p-Y19 CDK9) in ovarian and breast cancer [113].